Dyne Therapeutics, Inc.

NASDAQ:DYN

Biotechnology

Healthcare
$15.87 +1.97%

+$0.38 today

Market cap
$2.97B
Beta
1.08
P/E (TTM)
-7.2
EPS (TTM)
-$2.74
52W Low $8.06High $25.00

Volume 2.93M

Average 1.71M

DYN Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Dyne Therapeutics, Inc.NASDAQ: DYN

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit remains negative

Q2 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$521K.

Context

  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$130.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
-$2.05M+8.6% YoY
LTMJun 2026
-$521K— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+8.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(2.05M) USD
Year-over-year change
+8.6%

Gross Profit vs competitors

How DYN compares with its peers on the latest reported figures

  • DYN's LTM Jun 2026 gross profit of -$521K is the 7th highest of the 11 companies compared; the peer median is $14.49M.
DYN Competitors Peer median
Gross Profit for DYN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$1.36B -25.4%+18.4%62.4%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$942.72M -1.3%+17.4%98.2%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$828.57M -51.6%+36.4%82.1%
WVEWave Life Sciences Ltd.LTM Mar 2026$67.34M -34.5%+110.2%93.8%
STOKStoke Therapeutics, Inc.LTM Mar 2026$28.99M -84.7%+145.9%90.4%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 ———
DYNDyne Therapeutics, Inc.LTM Jun 2026-$521K ———
SLDBSolid Biosciences Inc.LTM Mar 2026-$781K -91.9%——
PEPGPepGen Inc.LTM Mar 2026-$1.72M -351.6%——
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-$34.31M -119.9%—598.0%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026-$42.41M -4.9%——
Peer median (excluding DYN) $14.49M-51.6%+36.4%92.1%

Competitors are the stored peer set for DYN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue002.46M2.24M2.05M
Gross Profit00(2.46M)(2.24M)(2.05M)
Gross Margin—————
Research & Development121.31M142.76M210.76M281.41M398.33M
Selling, General & Admin28.72M28.2M31.4M62.48M69.85M
Operating Expenses150.03M170.96M239.7M341.64M466.14M
Depreciation & Amortization1.09M1.68M1.67M1.67M2.05M
EBITDA(148.2M)(163.5M)(234.26M)(315.75M)(437.97M)
EBITDA Margin—————
Operating Income(150.03M)(170.96M)(242.16M)(343.89M)(468.18M)
Operating Margin—————
Interest Income742K2.92M7.64M26.92M29.86M
Interest Expense02.92M006.19M
Other Income / Expenses734K2.86M6.23M26.47M21.97M
Income Before Tax(149.29M)(168.1M)(235.94M)(317.42M)(446.21M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(149.29M)(168.1M)(235.94M)(317.42M)(446.21M)
Net Margin—————
EPS (Basic)(2.93)(3.23)(3.95)(3.37)(3.47)
EPS (Diluted)(2.93)(3.23)(3.95)(3.37)(3.47)
Weighted Avg Shares50.9M51.98M59.68M94.14M128.44M
Weighted Avg Shares (Diluted)50.9M51.98M59.68M94.14M128.44M

Dyne Therapeutics, Inc.

NASDAQ:DYN

Intrinsic Alpha fair value

Locked

Current Price

$15.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.